Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2014 Dec;28(6):1171-85. doi: 10.1016/j.hoc.2014.08.014. Epub 2014 Sep 29.

Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions.

Author information

1
9000 Rockville Pike, Building 10/9N112, Bethesda, MD 20892, USA.
2
Division of Blood and Marrow Transplantation, Children's National Health System, George Washington University School of Medicine and Health Sciences, 111 Michigan Avenue, North West, Washington, DC 20010, USA.
3
9000 Rockville Pike, Building 10/9N112, Bethesda, MD 20892, USA. Electronic address: matthewhs@mail.nih.gov.

Abstract

Research has solidified matched sibling marrow, cord blood, or mobilized peripheral blood as the best source for allogeneic hematopoietic stem cell transplantation for patients with sickle cell disease, with low graft rejection and graft-versus-host disease (GVHD) and high disease-free survival rates. Fully allelic matched unrelated donor is an option for transplant-eligible patients without HLA-matched sibling donors. Unrelated cord transplant studies reported high GVHD and low engraftment rates. Haploidentical transplants have less GVHD, but improvements are needed to increase the low engraftment rate. The decision to use unrelated cord blood units or haploidentical donors depends on institutional expertise.

KEYWORDS:

Cord blood (CB) donor; Haploidentical donor; Matched sibling donor; Matched unrelated donor; Sickle cell disease

PMID:
25459186
PMCID:
PMC4254544
DOI:
10.1016/j.hoc.2014.08.014
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center